Richard Adair, Virology Manager, SGS Vitrology Limited
Karin Agerman, CSO, CombiGene
Omar Aljitawi, Professor, University of Rochester Medical Center
Amina Al-Mossawi, Qualified Person, UCL/ Hitech Health
Nicola Ambler, Founder, The CGT Circle
Adrien Auffret Cariou, Team lead – Process Development Projects, SK Pharmteco
Michael Baker, Senior Director Viral Gene Therapy, FUJIFILM Diosynth Biotechnologies
Chris Baldwin, Senior Director of Cell and Gene Therapy Supply Chain, GlaxoSmithKline Plc
Robert Balfour, Investment Director, Alsa Ventures
Tomasz Baran, Executive VP, PBKM/FamiCord Group
Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield
Samantha Barber, Chief Executive Officer, Gene People
Kate Barclay, Skills Strategy Consultant, UK Bioindustry Association
Piotr Barski, Chief Executive Officer, University of Pisa
Pranetha Baskaran, Senior Programme Manager, MedCity
Roy Baynes, Senior Vice President Clinical Research, Eikon Therapeutics
Benedikt Berninger, Professor of Developmental Neurobiology, King's College London
Niklas Beschorner, Head of Rnd, PROVIREX Genome Editing Therapies GmbH
Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Simon Bornschein, Founder & Chief Executive Officer, coding.bio
John Bridgeman, Director of Cell Therapy Research, Instil Bio
Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, University of Sheffield
Oliver Brown, Project Lead, Life Sciences Hub Wales Ltd
Martina Brunati, vector process development manager, AGC Biologics
Emmanuelle Cameau, Strategic Technology Partnership Leader, Cytiva
Rafael Carazo Salas, Chief Executive Officer, CellVoyant Technologies Ltd
Gloria Carmona Sanchez, Scientific Coordinator, Andalusian Network for Advanced Therapies
Paul S Carter, Director, Head Vector Processing, Quell Therapeutics
Pedro Cejas, Head of New Therapeutic Modalities, Spark Therapeutics
Alex Chalk, Gene Therapy Research Assistant, UCL
Pascale Charbonnel, CBO, SCTbio
Farhad Chariyev-Prinz, Postdoc, University of Natural Resources and Life Sciences, Vienna
Fred Chereau, SVP, Strategy and Business Development, Alexion Pharmaceuticals
Klaus Cichutek, Former President, Paul Ehrlich Institute & Apl. Professor of Biochemistry, Goethe University Frankfurt
Lindsey Clarke, VP Commercial, The CGT Circle
Angela Columbano, Head Business Development Partnership, Genethon
Randolph Corteling, CSO, ReNeuron
Elena Costariol, DP MSAT Senior Scientist, Orchard Therapeutics
Scott Cribbes, Market Development Leader, Revvity
Montserrat Daban, Director of Strategic Foresight and International Relations, Biocat
Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy
Lindsay Davies, CSO, NextCell Pharma
Francesco Dazzi, Professor of Regenerative Medicine, King’s College London Executive & Medical Lead, Cell Therapy, AstraZeneca
Isaak Decoene, Senior Researcher, KU Leuven
Colleen Delaney, Founder, Chief Scientific Officer, Deverra Therapeutics, Inc.
Francesca Di Pasquale, Director R&D, QIAGEN GmbH
Michaela Diakatou, Global Product Manager for PSCs and MSCs Clinical Applications, Miltenyi Biotec GmbH
Graciana Diez Roux, Chief Scientific Officer, Tigem
Graciana Diez-Roux, Chief Scientific Officer, Telethon Institute of Genetics and Medicine
Victor Dillard, VP, Strategy & Operations, Resolution Therapeutics
Ben Doak, National Senior Programme of Care Manager (innovative treatments), NHS England
Marcus Droege, Senior Advisor, Market Access & Commercial, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Christian Dubiella, Technology Manager – Nucleic Acid Formulation, Wacker Chemie AG
Julian Dye, Founder & CEO, Oxartis Ltd
Simon Eaglestone, Director, Program Management, Bloomsbury Genetic Therapies
Thomas M. Ecker, Chief Executive Officer, Ecker+Ecker GmbH
Victoria English, Co-Founder And Editor, Evernow Publications
Seth Ettenberg, Chief Executive Officer And President, BlueRock Therapeutics
Lucia Faccio, Partner Sofinnova Telethon Fund, Sofinnova Partners
Edward Fahey, QCS Director, Scitech Engineering Ltd
Danielle Fairbrass, Group Lead, Cell Biology, coding.bio
Marcie Finney, Executive Director, Cleveland Cord Blood Center
Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics
Barry Flutter, Head of Product Manufacturing, GOSH
David Foldes, Senior Clinical Research Fellow, Imperial College London
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, Adbio partners
Tim Fugmann, CSO and Co-founder, Alithea Bio
Gonzalo Garcia, Investment Partner, Syncona
Saba Ghassemi, Assistant Professor, University of Pennsylvania
Cédric Ghevaert, Professor in Transfusion Medicine, University of Cambridge
Daniel Gibson, Director, Cell and Gene Therapy Services, Anthony Nolan
Kurt Gielen, Chief Business Officer, Medace
Paul Gissen, Professor of Metabolic Medicine, Head of Gene and Stem Cell Therapy, UCL Great Ormond Street Institute of Child Health
Janet Glassford, Senior Quality Assessor, Medicines & Healthcare products Regulatory Agency
Pedro Gonzalez-Alegre, Head of Gene Therapy Research, Spark Therapeutics
Tom Goodman, Partner, Cooley LLP
Mayur Goyal, Head, Commercial & Pipeline Strategy, Cell & Gene Therapies, Novartis
Roberto Gramignoli, Sr Researcher, Karolinska Institutet
David Greenwald, Vice President Of Business Development, Deerfield Management
Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperiai College London
Felipe Guapo, Analytical Scientist, NIBRT
Chris Hackley, Chief Executive Officer, Eucalyptus Bio
Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA
Patrick Hanley, Chief and Director, Cellular Therapy Program, Children's National Medical Center
Günter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Alexandra Harrison, PhD Student, University of Bristol
Thomas Hauser, Sales Director EMEA, C-Cube
David Hay, Chief Executive Officer, Stimuliver
Amir Hefni, VP, Global Commercial Head, Cell & Gene, Novartis
Sam Hickman, Field Application Specialist, Albumedix Ltd. - NOTTINGHAM
Edward Hodgkin, Managing Partner, Syncona
Kevin Holden, Head of Science, Synthego Corporation
Yi-Ting Hu, Researcher, University College London
Adam Inche, CEO, Lentitek
Melita Irving, Group Leader T-Cell Engineering, University of Lausanne
Ryotaro Ishikawa, Region Europe Gene Therapies Value and Access Head, Novartis
Kathy Ivey, Vice President of Gene Therapy Research, Tenaya Therapeutics
Russell Jarres, Sr. Manager, Strategic Collaborations, Thermo Fisher Scientific
Inge Jedema, Head of Translational Cellular Therapy, Netherlands Cancer Institute / Antoni van Leeuwenhoek
Pia Johansson, Director, Cell and Gene Therapy Core, Lund University
Jason Jones, Global Business Development Lead, Cellular Origins
Ron Jortner, Founder & Chief Executive Officer, Aspire Biosciences
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Angela Justice, Chief People Officer, Justice Group Advisors
Cornelia Kasper, Head of Institute for Cell and Tissue Culture Technologies, University Of Natural Resources And Life Sciences Vienna
Jasmin Kee, Bioprocessing Consultant, KeeBio
Kilian Kelly, Chief Executive Officer & Managing Director, Cynata Therapeutics Ltd
Sven Kili, Chief Development Officer, CCRM & Principal, Sven Kili Consulting
Laura Koivusalo, Chief Executive Officer & Founder, StemSight
Bence Kozma, Research Assistant PostDoc, TU Wien
David Kuntin, Chief Executive Officer, MesenBio
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Michael Kyriakides, Investment partner, Syncona Ltd
Pauline L' Hénaff, Head of Industry Engagement, Access to Medicine Foundation
Michele Lai, Researcher, University of Pisa
Marcos Langtry, Director, Commercial Development, CGT, Lonza
Holger Laux, Director of Viral Vector Process Development, CSL Behring
Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator (NATA)
Hanna Lesch, CTO, Exothera
Bruce Levine, Professor, Perelman School of Medicine University of Pennsylvania
Doreen Li, CFO, Santo Therapeutics
Roel Lievrouw, Downstream Process Development Manager, Exothera SA
Rosie Lindup, Policy and Public Affairs Manager, Bia
Gisela Linthorst, Head of Patient Engagement and Advocacy, Azafaros
Raquel Loreto, Scientist, Batavia Biosciences
Tarik Luisman, Director Bioinformatics & Digital Systems, GeneScape
John Maher, CSO, Leucid Bio
Alberto Malerba, Lecturer in Gene Therapy, royal holloway university of london
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Paolo Martini, CSO Rare Diseases, Hematology and Rare Alliances,, Moderna Therapeutics
Yoshiaki Maruyama, Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Julius Mathews, Project Manager & Research Fellow, Fraunhofer Institute for Production Technology IPT
Toni Mathieson, Chief Executive, Niemann-Pick UK
Vasily Medvedev, Head of Development, Exothera
Emily Merrell, Director of Centre for Cell & Gene Therapy, ICON PLC
Imen Mestiri, Business Development Manager, Genethon
Jo Miller, Director, Cell Therapy Sciences
Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Director Translational Skills, LifeArc
Diego Möckli, Head of TechOps Strategy and Supply Chain, Tigen Pharma
Deana Mohr, Chief Executive Officer, MUVON Therapeutics
Sandrine Morel, Research Scientist, Universite de Geneve
Ismael Moreno Sánchez, Margarita Salas Postdoctoral Researcher, University Pablo de Olavide de Sevilla
Sandrine Mores, COO, EXO Biologics
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
David Morrow, scientist, eatris
Phil Morton, CTO, Albumedix Ltd
Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Innovation Hubs for Gene Therapies
Matthias Müllner, Chief Executive Officer, bespark*bio
Julien Muzard, Field Applications Technologist, ENTEGRIS
Snehal Naik, Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics
Michael Nation, Director of Development, Kidney Reseach U.K.
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Jan Nelis, CEO & Co-Founder, Ariya Bio
Katy Newton, Senior Vice President of Immunology and Process Development, Achilles Therapeutics Limited
Joanne Ng, Senior Research Fellow, University College London
Josefina Nilsson, Chief Executive Officer, QuTEM AB
Roberto Nitsch, Director, Astrazeneca
Raphael Ognar, President & Chief Executive Officer, Co-Founder, NKILT Therapeutics Inc.
Willy Oliveira, Business Development Manager, Integra Therapeutics
Christina O'Neill, Chief Executive Officer, VascVersa
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
George Pamenter, PhD Researcher, UCL
Vashu Pamnani, Senior Business Development Manager, Research Donors
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Shree Patel, EVP Patient Supply Operations, Achilles Therapeutics Limited
Rik Patel, Senior Trade Manager, London & Partners
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Henry Pegram, Head of Business Development, Kings College London Gene Therapy Vector Facility
David Peritt, Chief Scientific Officer, Lupagen
Madhusudan Peshwa, CTO, Tessera Therapeutics
Carlotta Peticone, Principal Scientist, Orchard Therapeutics
Paola Pozzi, Partner, Sofinnova Partners
Thomas Prod'homme, Vice President, Translational Research, Myeloid Therapeutics
Amelie Quilichini, Chief Executive Officer and Co-Founder, Kolibri
Valentin Quiniou, CSO, Parean Biotechnologies
Vittoria Raffa, Professor, University of Pisa
Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London
Liz Ramsburg, Head of Neuroscience Research, Spark Therapeutics
Linda Randall, Associate VP, Biologics Development, Manufacturing & Control, Pharmaron
Lior Raviv, CTO, Pluri
Nicola Redfern, Director, NJ Redfern Ltd.
Thomas Robert, Product Manager, Univercells Technologies
Jessica Robinson, PD, Terrapinn
Josh Robinson, Chief Executive Officer, COCOON BIOSCIENCE
Andre Roeder, Head, Commercial Operations EU, TETEC AG
Sean Russell, Head of Translational Project Management & Regulatory Affairs, Telethon Foundation
Pooja Sabhachandani, Associate Director, Tessera Therapeutics
Tara Sadeghi, Chief Operating Officer, Cellenkos
Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics
Caroline Savage, Professor of Nephrology, University of Birmingham
Mark Sawicki, Chief Executive Officer, Cryoport Systems
Christian Schenk, Industry Lead Life Sciences, time matters
Fatma Senkesen, Executive Director, Head Divisional Projects C&G, Lonza
Tanya sharma, cofounder, Assurea LLC
Leigh Shaw, SVP, Head of Regulatory Affairs and Non-Clinical Safety, Toxicology & Biodistribution, Bloomsbury Genetic Therapies
Daniel Shelly, Vice President Business Development and Alliances, Prescient Therapeutics
Alex Shephard, Product Manager, Unchained Labs
Kevin Smith, Head of Technology Development: Synthetic Biology, Cell Line Development, Process Development, Asimov
Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
Owen Smith, Partner, 4BIO Capital
Ludek Sojka, Chief Executive Officer, SCTbio
Joseph Stavas, Senior Vice President of Clinical Development, ProKidney
Jenny Stjernberg, Commercial Director, EMEA, ScaleReady
Mark Stockdale, Senior Director of Strategic Alliances, Asimov
Matthias Stöcker, Capability Lead, Boehringer-Ingelheim
Nicola Stoner, Consultant Pharmacist, Oxford University Hospitals N.H.S. Trust
Stephen Sullivan, COO, iPSirius
Marina Tarunina, Research Director, Plasticell
George Tetley, CSO, Deliver Biosciences
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Steven Thompson, Vice President, Sales - Cell Processing, BioLife Solutions
Mya Thu, Co-Founder and Chief Executive Officer, Visicell Medical Inc.
Pamela Tranter, Head, Translational Research Group, Translational Research Office, University College London
Marco Traub, Chief Executive Officer, Tesct—Society
Prof. Dr. Andrea Tüttenberg, Chief Executive Officer, ActiTrexx GmbH
Christopher Ullman, Co-founder and Chief Executive Officer, Stratosvir Limited
Stefanie Urlinger, Chief Scientific Officer, Cimeio Therapeutics
Joris van Arensbergen, Chief Executive Officer, Annogen BV
Melissa van Pel, Head of Cell Therapy, NecstGen BV
Marijn Verhoef, Director of Research and Operations, Access to Medicine Foundation
Maria Jacintha Victoria, Analytical Development Team Lead, Rentschler Biopharma
Ketki Vispute, Associate Director of Production, Autolus
Michael von Forstner, Head of Safety Science, Global Pharmacovigilance and Patient Safety, Sobi (Swedish Orphan Biovitrum)
Ivan Wall, Professor, FourPlus Immersive Ltd.
Ruizhi Wang, Chief Executive Officer/Founder, Abselion
Natalie Ward, Director, Regulatory Affairs CMC, Adaptimmune
Neil Watson, Director Of Northern Alliance Attc, Northern Alliance Advanced Therapies Treatment Centre
Ben Weil, Director of Manufacturing, INmune Bio
Theodora Weisz, Head of Patient Advocacy and Public Affairs, Novartis Gene Therapies, Novartis Gene Therapies
Anna Louisa Weltin, Research Fellow, Fraunhofer IPT
Caroline Weydert, RSS genomics, Bio-Rad
Nathan White, Research Associate, UCL
Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Sue Williams, Managing Director, Hexagon Consultants Ltd.
Chris Williams, SVP, Corporate Development, Autolus Therapeutics
Andrew Willis, Chief Development and Regulatory Officer, Lift Biosciences Ltd
Debbie Worthing, Lead Research Nurse, Advanced Therapies Wales, Welsh Blood Service
Kris Wronski, Cell Culture Applications Scientist, Thermo Fisher Scientific
Sujeong Yang, Senior Research Scientist, Astrea Bioseparations
Kikuo Yasui, Chief Operating Officer, Director of the Board, Heartseed Inc.
Mana Yen, Global Executive Director - Health systems, Novartis Gene Therapies
Elisabetta Zanon, Director, European Policy and Advocacy, Alliance for Regenerative Medicine
Andrea Zobel, Senior Director Personalized Supply Chain, World Courier
Michela Zuccolo, Gene Therapy and Rare Strategy, F. Hoffmann-La Roche
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events